Volume 1.37 | Oct 1

Prostate Cell News 1.37, October 1, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Gene Variations that Alter Key Enzyme Linked to Prostate Cancer 
Researchers have found that variations in a gene for an enzyme involved in cell energy metabolism appear to increase the risk for prostate cancer. [Press release from the National Institutes of Health discussing online prepublication in The Journal of Clinical Endocrinology and Metabolism]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies


Interested in recruiting talented individuals? Post your career opportunities in Prostate Cell News at no cost. Contact us at [email protected]


Biomarker Panel Identifies Prostate Cancer with 90 Percent Accuracy
Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy. [Press release from the American Association for Cancer Research (AACR) discussing data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development]

Jevtana(R) Improves Survival in Advanced Prostate Cancer Patients
Sanofi-aventis announced that data from the Phase III TROPIC study, which was the basis for the U.S. Food and Drug Administration (FDA) approval of Jevtana® (cabazitaxel) Injection, was published. [Press release from Sanofi-aventis discussing online prepublication in The Lancet]

Surgery Found Effective for Patients with Aggressive Prostate Cancer
In one of the first studies to focus exclusively on the outcomes after treatment for patients with high-risk prostate cancer, researchers have found that surgery provides high survival rates. [Press release from Mayo Clinic Press Release discussing data presented at the North Central Section of the American Urological Association’s 84th Annual Meeting]

Watch Procedure Now  

Culture and Characterize Prostate Epithelial Progenitor Cells
with ProstaCult

by STEMCELL Technologies


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


LIM Kinases are Required for Invasive Path Generation by Tumor and Tumor-Associated Stromal Cells
Using siRNA-mediated knockdown or a novel small molecule inhibitor, researchers show LIMK was required for path generation by leading tumor cells and nontumor stromal cells during collective tumor cell invasion. [J Cell Biol]

Sildenafil Increases Chemotherapeutic Efficacy of Doxorubicin in Prostate Cancer and Ameliorates Cardiac Dysfunction
Researchers have shown that the potent phosphodiesterase-5 (PDE-5) inhibitor sildenafil (Viagra) induces a powerful effect on reduction of infarct size following ischemia/reperfusion injury and improvement of left ventricular dysfunction in the failing heart after myocardial infarction or doxorubicin (DOX) treatment. [Proc Natl Acad Sci USA]

Androgens Suppress EZH2 Expression Via Retinoblastoma (RB) and p130-Dependent Pathways: A Potential Mechanism of Androgen-Refractory Progression of Prostate Cancer
The results reveal that androgens function as an epigenetic regulator in prostatic cells by repression of EZH2 expression through the retinoblastoma protein and p130-dependent pathways. [Endocrinology]

Polymorphic Variation in the Androgen Receptor Gene: Association with Risk of Testicular Germ Cell Cancer and Metastatic Disease
The findings strengthen the hypothesis of the importance of androgen action in the aetiology and pathogenesis of testicular malignancy. [Eur J Cancer]

CD4 T Cell-Mediated Immune Response to Prostatic Proteins in HLA-DRB1*1503 Transgenic Mice and Identification of a Novel HLA-DRB1*1503-Restricted T Cell Epitope From Human Prostatic Acid Phosphatase
The data demonstrate a disparity in CD4 T cell immune reactivity to prostate-specific antigen and prostatic acid phosphatase between HLA-DRB1*1501 and -DRB1*1503 alleles in human leukocyte antigen transgenic mouse models. It is possible that such immunological differences could contribute to racial disparity in prostate cancer outcome. [Prostate]


Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-Label Trial
Researchers aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment. [Lancet]

DDPC: Dragon Database of Genes Associated with Prostate Cancer
Researchers have developed Dragon Database of Genes associated with Prostate Cancer (DDPC) as an integrated knowledgebase of genes experimentally verified as implicated in prostate cancer. [Nucleic Acids Res]

Structural Decay of Bone Microarchitecture in Men with Prostate Cancer Treated with Androgen Deprivation Therapy
Researchers investigated changes in bone microarchitecture in 26 men with nonmetastatic prostate cancer during the first year of androgen deprivation therapy using the new technique of high-resolution peripheral quantitative computed tomography. [J Clin Endocrinol Metab]

Presence of the Metabolic Syndrome is Associated with Shorter Time to Castration-Resistant Prostate Cancer
This preliminary data suggest that metabolic syndrome is a risk factor for earlier development of castration-resistant prostate cancer and support the need for a prospective evaluation of this finding. [Ann Oncol]


OncoGenex Pharmaceuticals Announces Initiation of a Phase II Trial Evaluating OGX-427 Treatment in Men with Advanced Prostate Cancer
OncoGenex Pharmaceuticals, Inc. announced the initiation of a randomized, controlled, investigator-sponsored Phase II trial of OGX-427 in men with metastatic prostate cancer. [OncoGenex Pharmaceuticals, Inc. Press Release]

Nanobubbles Get a Boost
Lapotko’s Plasmonic Nanobubble Lab, a joint American-Belarusian laboratory for fundamental and biomedical nanophotonics, has received an R01 grant worth more than $1 million over the next four years to continue developing a method to track down individual cancer cells and destroy them in a single process. [Rice University Press Release]

Warburg Pincus Agrees to Invest Up to $35 Million in Protox
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, jointly announced that they have entered into an Investment Agreement. [Protox Therapeutics Inc. Press Release]

Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
Dendreon Corporation announced PROVENGE(R) (sipuleucel-T) data presentations taking place at the 25th International Society for Biological Therapy of Cancer (iSBTc) annual meeting in Washington, D.C. [Dendreon Corporation Press Release]

AstraZeneca’s Zibotentan Flunks Late-Stage Prostate Cancer Trial
AstraZeneca has suffered a setback in its oncology drug development strategy. The pharma giant reported that the closely watched prostate cancer therapy zibotentan failed a late-stage trial. [FierceBiotech]


NIH Grants Will Advance Studies of the Form and Function of Proteins
The National Institutes of Health has awarded 23 grants for structural biology research totaling up to $290 million over five years. [National Institutes of Health, United States]

NCBI Launches the Database of Genomic Structural Variations
The National Institutes of Health announced the launch of a new resource, called the Database of Genomic Structural Variation, or dbVar, to help scientists understand how differences in DNA contribute to human health and disease. [National Institutes of Health, United States]

NIH Releases Biennial Report of the Director
Dr. Francis S. Collins, M.D., Ph.D, director of the National Institutes of Health, announced the release of the Biennial Report of the Director, NIH, for fiscal years 2008 and 2009. The report provides an integrated portrait of NIH research activities, making it easy for Congress, advocates and patient groups and the general public to understand the many activities of the agency. [National Institutes of Health, United States]

The NCI Cancer Immunotherapy Trials Network (CITN) Seeks Member Clinical Sites (NOT-CA-10-034) [National Institutes of Health, United States]

Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR [U43/U44]) (PAR-10-286) [National Institutes of Health, United States]

Office of Biotechnology Activities, Office of Science Policy, Office of the Director; Notice of Meeting (FR Doc. 2010-23947) [National Institutes of Health, United States]

National Center for Research Resources; Notice of Closed Meeting (FR Doc. 2010-23852) [National Institutes of Health, United States]

Center for Scientific Review; Amended Notice of Meeting (FR Doc. 2010-23847) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-23849) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23860) [National Institutes of Health, United States]

EVENTS (Listed by Date)

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

American Association for Cancer Research (AACR) Translational Cancer Research for Basic Scientists
October 17-22, 2010
Boston, United States

6th Modern Drug Discovery & Development Summit (M3D)
October 20-22, 2010
San Francisco, United States

American Institute for Cancer Research (AICR) 2010 Annual Cancer Research Conference
October 21-22, 2010
Washington, DC, United States

MENA Oncology Conference
October 22-23, 2010
Cairo, Egypt

Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

Select Biosciences 3rd Annual Molecular Diagnostics World Congress
October 28-29, 2010
San Diego, United States

UAE Cancer Congress 2010
October 28-30, 2010
Dubai, United Arab Emirates

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom

9th Annual American Association for Cancer Research (AACR) International Conference: Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

22nd European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) Symposium: Molecular Targets and Cancer Therapeutics
November 16-19, 2010
Berlin, Germany

Cancer Pharmacogenetics: Personalizing Medicine
November 22-24, 2010
Madrid, Spain

The 10th Annual Meeting of the Society Of Urologic Oncology (SUO) – 10th Annual Winter Meeting
December 3-5, 2010
Bethesda, United States

33rd Annual San Antonio Breast Cancer Symposium
December 8-12, 2010
San Antonio, United States

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

IMPaCT: Innovative Minds in Prostate Cancer Today 2011
March 9-12, 2011
Orlando, United States

The 6th International Conference on Oncolytic Viruses as Cancer Therapeutics
March 16-19, 2011
Las Vegas, United States

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

American Association for Cancer Research (AACR) Cancer Research Imaging Camp
June 19-24, 2011
St. Louis, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Prostate Cell News at no cost.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us